Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BBIO
BBIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BBIO News
BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT
2d ago
moomoo
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
2d ago
Benzinga
BridgeBio Pharma Shares Surge 13% After Successful Phase 3 Trial of Infigratinib
3d ago
seekingalpha
BridgeBio Reports Positive Phase-3 Data for Infigratinib
3d ago
stocktwits
BridgeBio Reports Positive Results from PROPEL 3 Study
3d ago
Newsfilter
U.S. Markets End Thursday in Decline; Estee Lauder Experienced the Largest Drop
Feb 05 2026
Barron's
NASDAQ 100 Pre-Market Indicator Rises 126.58 to 25,673.66
Jan 16 2026
NASDAQ.COM
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected
Jan 16 2026
seekingalpha
BridgeBio Pharma Prices $550 Million Convertible Notes Offering
Jan 16 2026
NASDAQ.COM
BridgeBio Pharma Prices $550 Million Convertible Notes at 0.75% Interest Rate
Jan 16 2026
Globenewswire
BridgeBio Pharma (BBIO) Plans $550 Million Convertible Notes Offering
Jan 14 2026
seekingalpha
BridgeBio Reports $146 Million in Attruby Product Revenue for Q4 2025
Jan 12 2026
Globenewswire
Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target
Jan 06 2026
CNBC
BridgeBio to Host Investor Webinar on Achondroplasia Treatment Insights
Jan 02 2026
Globenewswire
U.S. Markets Declined on Wednesday; QXO Experienced the Largest Drop
Dec 31 2025
Barron's
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Show More News
